CN201880193U - Slowly-releasing chemotherapy needle - Google Patents
Slowly-releasing chemotherapy needle Download PDFInfo
- Publication number
- CN201880193U CN201880193U CN2010205909963U CN201020590996U CN201880193U CN 201880193 U CN201880193 U CN 201880193U CN 2010205909963 U CN2010205909963 U CN 2010205909963U CN 201020590996 U CN201020590996 U CN 201020590996U CN 201880193 U CN201880193 U CN 201880193U
- Authority
- CN
- China
- Prior art keywords
- chemotherapy
- puncture
- needle body
- sustained
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model relates to the field of medical devices, and discloses a slowly-releasing chemotherapy needle which comprises a needle body 1 and a needle tail 2, and the surface of the needle body 1 is provided with various chemotherapy drugs and thrombin. Because the head of the needle body 1 is sharp, multi-point puncture local chemotherapy can be carried out to a huge malignant tumor; and the needle tail 2 which is similar to the umbrella part of a thumbtack can be used for the force application when in puncture and the hemostasis to puncture points after puncture. Through a simple structure, the 'acupuncture' chemotherapy can be carried out to the tumor when the huge malignant tumor cannot be cut in a surgery, the slowly released drugs can significantly improve the local drug concentration, so that the chemotherapy effect is enhanced, and the tumor burden and drug toxicity during a post-chemotherapy process are reduced.
Description
Technical field
This utility model relates to medical apparatus and instruments, particularly the chemotherapy apparatus in the medical apparatus and instruments.
Background technology
In recent years, the sickness rate of children's's malignant tumor rises gradually, and along with the cure rate of infectious disease improves, and children's's malignant tumor has become children's's one of reason of mainly dying of illness.In the U.S., children's's malignant tumor continues to increase with per 5 years 4.0% speed, and in children's's cause of death with 10% occupy the 2nd at high proportion, be only second to 44.0% of unexpected death.It is significantly different that the characteristics of incidence of children's's malignant tumor and adult have, and embryo's property tumor accounts for 50.0%～60.0%, and the modal epithelial cancer of being grown up only is 3.0%～9.0% the child.The male is obviously more than the women, age of onset is two peaks trend, about 35.0%～50.0% morbidity within 3 years old, mostly be embryo's property tumors such as neuroblastoma, nephroblastoma, pernicious germ cell tumor, another onset peak is a prepuberty, mostly is " hebephrenictype " malignant tumor such as hepatocellular carcinoma, thyroid carcinoma, osteosarcoma.
Chemotherapy plays an important role in the treatment of kinds of tumors as a kind of important method of oncotherapy.But, limited the tumor raising of partial drug level on every side because vein uses various chemotherapeutics can produce more toxic and side effects.So a remarkable advantage of local chemotherapy is to have reduced chemotherapeutic toxicity.Because concentration is low in the conventional chemotherapy tumor, most of medicine is in other organ effect of body, and toxic and side effects is obvious.Therefore with respect to conventional chemotherapy, local chemotherapy only acts on the part, and the whole body toxic and side effects is few, can improve patient's life quality.
But,, also be confined to sustained-release micro-spheres and local stick or the membrane implanted at present to the localization therapy of huge malignant entity tumor.And this mode can't realize huge malignant entity tumor is carried out multiple spot puncture local chemotherapy, still has certain shortcoming on curative effect.
The utility model content
The purpose of this utility model is to provide a kind of sustained-release chemotherapy pin, when huge malignant entity tumor operation can't be excised, tumor is carried out " acupuncture " formula sustained-release chemotherapy, strengthens the effect of chemotherapy, tumor load and drug toxicity reaction during reduction later stage chemotherapy.
For solving the problems of the technologies described above, embodiment of the present utility model provides a kind of sustained-release chemotherapy pin, comprises needle body 1 and backshank 2;
This utility model embodiment compared with prior art, the main distinction and effect thereof are:
Constitute a kind of sustained-release chemotherapy pin by needle body 1 and backshank 2, on the surface of its needle body 1, have various chemotherapeutics.Because the head of needle body 1 is sharp-pointed, can carry out multiple spot puncture local chemotherapy to huge malignant entity tumor; And the backshank 2 of similar drawing pin umbrella portion, the hemostasis by compression of back of putting forth effort and puncture when can be used for puncturing to point of puncture.By simple structure, can carry out " acupuncture " formula chemotherapy to tumor when huge malignant entity tumor operation can't be excised, slowly the medicine that discharges can significantly increase local drug concentration, strengthen the effect of chemotherapy, tumor load and drug toxicity reaction during reduction later stage chemotherapy.
Further, sustained-release chemotherapy is made by polylactic-co-glycolic acid copolymer p LGA with pin, makes this needle set that certain sharp property and hardness be arranged, and can be punctured to the deep of huge entity tumor comparatively smoothly.And polylactic-co-glycolic acid copolymer p LGA not only has mechanical strength, toughness and hot formability preferably, and as a kind of pharmaceutical carrier, possess nontoxic in vivo, excellent biological compatibility is arranged, biodegradable, can slowly discharge characteristics such as medicine enduringly, because slowly the medicine that discharges can significantly increase local drug concentration, therefore can further strengthen the effect of chemotherapy, tumor load and drug toxicity reaction during reduction later stage chemotherapy.
Further, the surface of needle body 1 also has thrombin except that having chemotherapeutics.Owing to not only have various chemotherapeutics on the surface of needle body 1, also have thrombin, therefore in the effect of performance chemotherapy, can bring into play promotion chemotherapy pin thrombosis on every side by the thrombin that has, reduce the blood supply of tumor tissues, the effect of inducing apoptosis of tumour cell, thus the effect of chemotherapy strengthened.
Description of drawings
Fig. 1 is the sustained-release chemotherapy needle construction sketch map according to this utility model one better embodiment.
The specific embodiment
In the following description, in order to make the reader understand the application better many ins and outs have been proposed.But, persons of ordinary skill in the art may appreciate that even without these ins and outs with based on the many variations and the modification of following each embodiment, also can realize each claim of the application technical scheme required for protection.
For making the purpose of this utility model, technical scheme and advantage clearer, embodiment of the present utility model is described in further detail below in conjunction with accompanying drawing.
This utility model one better embodiment relates to a kind of sustained-release chemotherapy pin.Fig. 1 is the structural representation of this sustained-release chemotherapy with pin, and this sustained-release chemotherapy comprises needle body 1 and backshank 2 with pin, and (PLGA) makes by the polylactic-co-glycolic acid copolymer.
Specifically, this needle body 1 is elongated, and needle section is sharp-pointed, and cross section is circular, and diameter is about 1-5mm, and length does not wait from 5cm to 20cm.The surface of needle body 1 has various chemotherapeutics and thrombin.Backshank 2 is umbrella, is similar to the umbrella portion of drawing pin, and diameter is 1-2cm.Because this backshank 2 is similar to the umbrella portion of drawing pin, therefore can put forth effort at this, be beneficial to the puncture of pin, and after puncture, point of puncture had the effect of hemostasis by compression.
Be not difficult to find, sustained-release chemotherapy in the present embodiment is simple with needle construction, when huge malignant entity tumor operation can't be excised, can realize tumor is carried out " acupuncture " formula chemotherapy, strengthen the effect of chemotherapy, tumor load and drug toxicity reaction during reduction later stage chemotherapy.
What deserves to be mentioned is, polylactic-co-glycolic acid copolymer (PLGA) is as a kind of new pharmaceutical carrier, and is nontoxic in vivo, and excellent biological compatibility is arranged, biodegradable, its catabolite can participate in the human body metabolism in vivo and finally be converted into carbon dioxide and water; In addition, it can slowly discharge medicine enduringly, and has mechanical strength, toughness and hot formability preferably.After the various slow release formulations of being made by poly-(lactic acid-hydroxyacetic acid) and medicament mixed were implanted diseased regions, medicine played consistently effect from wherein slowly releasing in localized sustained, is release time one month.Poly-simultaneously (lactic acid-hydroxyacetic acid) carrier is degraded to lactic acid and glycolic gradually, is absorbed by body.
Therefore, in the present embodiment, LGA makes the needle body that the surface has various chemotherapeutics and thrombin by the polylactic-co-glycolic acid copolymer p, makes this needle set that certain sharp property and hardness be arranged, and can be punctured to the deep of huge entity tumor comparatively smoothly.And polylactic-co-glycolic acid copolymer p LGA is as a kind of pharmaceutical carrier, possess nontoxicly in vivo, excellent biological compatibility is arranged, characteristic such as biodegradable, and can slowly discharge medicine enduringly, and have mechanical strength, toughness and hot formability preferably.Therefore can further strengthen the effect of chemotherapy, tumor load and drug toxicity reaction during reduction later stage chemotherapy.
In addition, owing to not only have various chemotherapeutics on the surface of needle body 1, also have thrombin, therefore in the effect of performance chemotherapy, can bring into play promotion chemotherapy pin thrombosis on every side by the thrombin that has, reduce the blood supply of tumor tissues, the effect of inducing apoptosis of tumour cell.
Though by reference some preferred implementation of the present utility model, this utility model is illustrated and describes, but those of ordinary skill in the art should be understood that and can do various changes to it in the form and details, and do not depart from spirit and scope of the present utility model.
Claims (6)
1. a sustained-release chemotherapy pin is characterized in that, comprises needle body (1) and backshank (2);
Described needle body (1) is elongated, and needle section is sharp-pointed, and the surface of described needle body (1) has the sustained-release chemotherapy medicine;
Described backshank (2) is umbrella, the hemostasis by compression of back to point of puncture of putting forth effort and puncture when being used to puncture.
2. sustained-release chemotherapy pin according to claim 1 is characterized in that, described sustained-release chemotherapy is made by polylactic-co-glycolic acid copolymer p LGA with pin.
3. sustained-release chemotherapy pin according to claim 1 is characterized in that, the surface of described needle body (1) also has thrombin.
4. according to each described sustained-release chemotherapy pin in the claim 1 to 3, it is characterized in that the cross section of described needle body (1) is circular, diameter is between 1mm to 5mm.
5. sustained-release chemotherapy pin according to claim 4 is characterized in that, described needle body (1) length is more than or equal to 5cm and be less than or equal to 20cm.
6. according to each described sustained-release chemotherapy pin in the claim 1 to 3, it is characterized in that, the diameter of described backshank (2) at 1cm between-the 2cm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010205909963U CN201880193U (en) | 2010-11-04 | 2010-11-04 | Slowly-releasing chemotherapy needle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010205909963U CN201880193U (en) | 2010-11-04 | 2010-11-04 | Slowly-releasing chemotherapy needle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201880193U true CN201880193U (en) | 2011-06-29 |
Family
ID=44177716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010205909963U Expired - Fee Related CN201880193U (en) | 2010-11-04 | 2010-11-04 | Slowly-releasing chemotherapy needle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201880193U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462887A (en) * | 2010-11-04 | 2012-05-23 | 上海交通大学医学院附属上海儿童医学中心 | Needle for sustained-release chemotherapy |
-
2010
- 2010-11-04 CN CN2010205909963U patent/CN201880193U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462887A (en) * | 2010-11-04 | 2012-05-23 | 上海交通大学医学院附属上海儿童医学中心 | Needle for sustained-release chemotherapy |
| CN102462887B (en) * | 2010-11-04 | 2014-06-25 | 上海交通大学医学院附属上海儿童医学中心 | Needle for sustained-release chemotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Bilayer dissolving microneedle array containing 5-fluorouracil and triamcinolone with biphasic release profile for hypertrophic scar therapy | |
| Greish | Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? | |
| He et al. | Hyalase-mediated cascade degradation of a matrix barrier and immune cell penetration by a photothermal microneedle for efficient anticancer therapy | |
| WO2018226160A1 (en) | Microneedle patch loaded with a fat browning agent and a method for preparing the same | |
| CN103505743A (en) | Cell micro-particles containing functional microRNA/siRNA and application thereof | |
| CN111870806A (en) | Magnetic control microneedle robot and preparation method, use method and application thereof | |
| Amourizi et al. | Polymeric and composite-based microneedles in drug delivery: regenerative medicine, microbial infection therapy, and cancer treatment | |
| Lin et al. | Recent advances in microneedles for tumor therapy and diagnosis | |
| Huang et al. | A microneedle patch for breast cancer screening via minimally invasive interstitial fluid sampling | |
| CN201880193U (en) | Slowly-releasing chemotherapy needle | |
| Chen et al. | Layered GelMA/PEGDA hydrogel microneedle patch as an intradermal delivery system for hypertrophic scar treatment | |
| CN207822261U (en) | A kind of radioactive particle chain connected using high molecular polymer connecting tube | |
| CN103110567A (en) | Preparation method of nanometer drug delivery system carrying tanshinone IIA and application thereof | |
| CN102462887B (en) | Needle for sustained-release chemotherapy | |
| Zaroo et al. | Giant lipoma: a case report | |
| CN115804842A (en) | Dacarbazine nano microneedle preparation as well as preparation method and application thereof | |
| Hagan et al. | Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment | |
| CN115282045A (en) | Hydrogel accurate delivery system based on acupuncture needle, preparation method and application | |
| CN109498547B (en) | Pingyangmycin local injection preparation and preparation method thereof | |
| CN114848577A (en) | Double-layer conductive microneedle patch for treating subcutaneous tumors and preparation method and application thereof | |
| Li et al. | Advances in the Study of Bioactive Nanoparticles for the Treatment of HCC and Its Postoperative Residual Cancer | |
| CN202821734U (en) | Magnetism alimentary canal support combined with hydrogel drug sustained release technology | |
| CN103110568A (en) | Nanometer drug delivery system carrying tanshinone IIA | |
| Meissner et al. | A solid erythematous tumour | |
| Duncan | The future of skin tightening: mechanical or biological? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 Termination date: 20151104 |
|
| EXPY | Termination of patent right or utility model |